Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LRAT | O95237 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AMY2A | P04746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067007 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL26736014 | 0.93 | AMY2A (0.51) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14600975 | 0.91 | MEN1 (0.41) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL17879097 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL17480019 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL23640180 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL26471008 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL19074567 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL12454820 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14639596 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148030-A1 | KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230346824-A1 | MEANS AND METHODS OF PREVENTING AND TREATING INFECTIONS | SOLYPLUS GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230173142-A1 | BALLISTIC DELIVERY TO MULTILAYERED TISSUES AND RELATED PARTICLES, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346824-A1 | MEANS AND METHODS OF PREVENTING AND TREATING INFECTIONS | CHIT1, MASP2, CHIA | MEN1 367/4885LRAT 1077/4885TRPV1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.